Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

28.54 -0.51 (-1.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,247,603
Open 29.67
Bid (Size) 28.54 (25)
Ask (Size) 28.56 (4)
Prev. Close 29.05
Today's Range 28.33 - 30.02
52wk Range 15.81 - 41.06
Shares Outstanding 101,298,669
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor was a buyer at the end of a very volatile trading week. 
Via The Motley Fool
Cathie Wood's Ark Invest Continues Loads Up On $6.05M Worth Of Robinhood Shares Amid Bitcoin Rebound, Dumps Zoom Stock
On Thursday, Cathie Wood-led Ark Invest made some significant trades, notably buying Robinhood Markets Inc (NASDAQ:HOOD) and selling Zoom Video Communications Inc (NASDAQ:ZM). 
Via Benzinga

Performance

YTD
+7.66%
+7.66%
1 Month
-9.51%
-9.51%
3 Month
+10.83%
+10.83%
6 Month
+29.43%
+29.43%
1 Year
-19.36%
-19.36%

More News

Read More
Guardant Health to Participate in Upcoming Investor Conferences
From Guardant Health, Inc.
Via Business Wire
Key Takeaways From Guardant Health Analyst Ratings
Via Benzinga
GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
Assessing Guardant Health: Insights From 7 Financial Analysts
Via Benzinga
Where Guardant Health Stands With Analysts
Via Benzinga
Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance
From Guardant Health, Inc.
Via Business Wire
Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat
Via Investor's Business Daily
Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer
From Guardant Health, Inc.
Via Business Wire
Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Via The Motley Fool
FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption
Via Benzinga
Exposures Product Safety
Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024
From Guardant Health, Inc.
Via Business Wire
Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance
From Guardant Health, Inc.
Via Business Wire
Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns
Via InvestorPlace
3 Precision Medicine Stocks Tailoring Treatments
Via InvestorPlace
Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast
Via Benzinga
Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors
From Guardant Health, Inc.
Via Business Wire
3 Biotech Moonshots With Imminent Catalyst Potential
Via InvestorPlace
The 3 Best Personalized Medicine Stocks to Buy in July 2024
Via InvestorPlace
From ‘Sell’ to ‘Strong Buy’: 3 Dramatic Analyst U-Turns to Watch
Via InvestorPlace
Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
From Guardant Health, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.